JP2006241144A5 - - Google Patents

Download PDF

Info

Publication number
JP2006241144A5
JP2006241144A5 JP2006024024A JP2006024024A JP2006241144A5 JP 2006241144 A5 JP2006241144 A5 JP 2006241144A5 JP 2006024024 A JP2006024024 A JP 2006024024A JP 2006024024 A JP2006024024 A JP 2006024024A JP 2006241144 A5 JP2006241144 A5 JP 2006241144A5
Authority
JP
Japan
Prior art keywords
phenyl
thiopyran
oxoethyl
tetrahydro
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006024024A
Other languages
Japanese (ja)
Other versions
JP5011739B2 (en
JP2006241144A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2006024024A priority Critical patent/JP5011739B2/en
Priority claimed from JP2006024024A external-priority patent/JP5011739B2/en
Publication of JP2006241144A publication Critical patent/JP2006241144A/en
Publication of JP2006241144A5 publication Critical patent/JP2006241144A5/ja
Application granted granted Critical
Publication of JP5011739B2 publication Critical patent/JP5011739B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (8)

下記一般式（Ｉ）で示されるＮ−｛２−[（４−置換フェニル）アミノ]−２−オキソエチル｝テトラヒドロ−２Ｈ−チオピラン−４−カルボキサミド化合物を有効成分とする医薬組成物。
Figure 2006241144
 （式中の記号は以下の意味を示す。
Ｚ：１，２，４−オキサジアゾール−３−イル又は４−オキサゾリル基、
Ａ：少なくとも１つのメチル基で置換され、更にメチル基及びハロゲン原子からなる群から選択される１〜２個の置換基を有していてもよいフェニル基、又は５−インダニル基。） A pharmaceutical composition comprising an N- {2-[(4-substituted phenyl) amino] -2-oxoethyl} tetrahydro-2H-thiopyran-4-carboxamide compound represented by the following general formula (I) as an active ingredient.
Figure 2006241144
 (The symbols in the formula have the following meanings.
Z: 1,2,4-oxadiazol-3-yl or 4-oxazolyl group,
A: A phenyl group which is substituted with at least one methyl group, and may further have 1 to 2 substituents selected from the group consisting of a methyl group and a halogen atom, or a 5-indanyl group. ) 抗ヘルペスウイルス剤である請求項１記載の医薬組成物。 The pharmaceutical composition according to claim 1, which is an anti-herpesvirus agent. 抗水痘帯状疱疹ウイルス剤である請求項２記載の医薬組成物。 The pharmaceutical composition according to claim 2, which is an anti- Varicella-zoster virus agent. 抗単純ヘルペスウイルス剤である請求項２記載の医薬組成物。 The pharmaceutical composition according to claim 2, which is an anti-herpes simplex virus agent. 一般式（Ｉ）中のＺが１，２，４−オキサジアゾール−３−イル基である、請求項１から４に記載の医薬組成物。The pharmaceutical composition according to claims 1 to 4, wherein Z in the general formula (I) is a 1,2,4-oxadiazol-3-yl group. 一般式（Ｉ）中のＺが４−オキサゾリル基である、請求項１から４に記載の医薬組成物。The pharmaceutical composition according to claims 1 to 4, wherein Z in the general formula (I) is a 4-oxazolyl group. 一般式（Ｉ）中のＡが少なくとも１つのメチル基で置換され、更にメチル基及びハロゲン原子からなる群から選択される１〜２個の置換基を有していてもよいフェニル基である、請求項１から６に記載の医薬組成物。A in the general formula (I) is a phenyl group which is substituted with at least one methyl group and may further have 1 to 2 substituents selected from the group consisting of a methyl group and a halogen atom. The pharmaceutical composition according to claims 1-6. N-(2,6-ジメチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(4-メチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(3-メチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(2-メチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(2,4-ジメチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(3,4-ジメチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(2,3-ジヒドロ-1H-インデン-5-イル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(4-クロロ-3-メチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(3-フルオロ-4-メチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(3-フルオロ-2,4-ジメチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(3,5-ジフルオロ-4-メチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(2-フルオロ-4-メチルフェニル)-N-(2-{[4-(1,3-オキサゾール-4-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(2,3-ジメチルフェニル)-N-(2-{[4-(1,2,4-オキサジアゾール-3-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(2,4-ジメチルフェニル)-N-(2-{[4-(1,2,4-オキサジアゾール-3-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(2,6-ジメチルフェニル)-N-(2-{[4-(1,2,4-オキサジアゾール-3-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(4-フルオロ-2,6-ジメチルフェニル)-N-(2-{[4-(1,2,4-オキサジアゾール-3-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(2,3-ジヒドロ-1H-インデン-5-イル)-N-(2-{[4-(1,2,4-オキサジアゾール-3-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(3-フルオロ-4-メチルフェニル)-N-(2-{[4-(1,2,4-オキサジアゾール-3-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、
N-(4-クロロ-3-メチルフェニル)-N-(2-{[4-(1,2,4-オキサジアゾール-3-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド、及び
N-(3-フルオロ-2,4-ジメチルフェニル)-N-(2-{[4-(1,2,4-オキサジアゾール-3-イル)フェニル]アミノ}-2-オキソエチル)テトラヒドロ-2H-チオピラン-4-カルボキサミド 1,1-ジオキシド
からなる群から選択される化合物を有効成分とする請求項１から４に記載の医薬組成物。 N- (2,6-dimethylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran-4-carboxamide 1 , 1-dioxide,
N- (4- Methylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran-4-carboxamide 1,1 -Dioxide,
N- (3 -methylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran-4-carboxamide 1,1 -Dioxide,
N- (2 -methylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran-4-carboxamide 1,1 -Dioxide,
N- (2,4- Dimethylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran-4-carboxamide 1 , 1-dioxide,
N- (3,4- Dimethylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran-4-carboxamide 1 , 1-dioxide,
N- (2,3 -dihydro-1H-inden-5-yl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H -Thiopyran-4-carboxamide 1,1-dioxide,
N- (4- Chloro-3-methylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran-4- Carboxamide 1,1-dioxide,
N- (3- Fluoro-4-methylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran-4- Carboxamide 1,1-dioxide,
N- (3- Fluoro-2,4-dimethylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran- 4-carboxamide 1,1-dioxide,
N- (3,5- difluoro-4-methylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran- 4-carboxamide 1,1-dioxide,
N- (2- fluoro-4-methylphenyl) -N- (2-{[4- (1,3-oxazol-4-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran-4- Carboxamide 1,1-dioxide,
N- (2,3- dimethylphenyl) -N- (2-{[4- (1,2,4-oxadiazol-3-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran- 4-carboxamide 1,1-dioxide,
N- (2,4- dimethylphenyl) -N- (2-{[4- (1,2,4-oxadiazol-3-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran- 4-carboxamide 1,1-dioxide,
N- (2,6- dimethylphenyl) -N- (2-{[4- (1,2,4-oxadiazol-3-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H-thiopyran- 4-carboxamide 1,1-dioxide,
N-(4-fluoro-2,6-dimethylphenyl) -N- (2 - {[4- (1,2,4- oxadiazol-3-yl) phenyl] amino} -2-oxoethyl) tetrahydro - 2H-thiopyran-4-carboxamide 1,1-dioxide,
N- (2,3 -Dihydro-1H-inden-5-yl) -N- (2-{[4- (1,2,4-oxadiazol-3-yl) phenyl] amino} -2-oxoethyl ) Tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide,
N- (3- Fluoro-4-methylphenyl) -N- (2-{[4- (1,2,4-oxadiazol-3-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H- Thiopyran-4-carboxamide 1,1-dioxide,
N- (4- Chloro-3-methylphenyl) -N- (2-{[4- (1,2,4-oxadiazol-3-yl) phenyl] amino} -2-oxoethyl) tetrahydro-2H- Thiopyran-4-carboxamide 1,1-dioxide, and
N- (3- Fluoro-2,4-dimethylphenyl) -N- (2-{[4- (1,2,4-oxadiazol-3-yl) phenyl] amino} -2-oxoethyl) tetrahydro- 2H-thiopyran-4-carboxamide 1,1-dioxide
The pharmaceutical composition according to any one of claims 1 to 4, which comprises a compound selected from the group consisting of:
JP2006024024A 2005-02-03 2006-02-01 Pharmaceutical composition containing tetrahydro-2H-thiopyran-4-carboxamide derivative Active JP5011739B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006024024A JP5011739B2 (en) 2005-02-03 2006-02-01 Pharmaceutical composition containing tetrahydro-2H-thiopyran-4-carboxamide derivative

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005028196 2005-02-03
JP2005028196 2005-02-03
JP2006024024A JP5011739B2 (en) 2005-02-03 2006-02-01 Pharmaceutical composition containing tetrahydro-2H-thiopyran-4-carboxamide derivative

Publications (3)

Publication Number Publication Date
JP2006241144A JP2006241144A (en) 2006-09-14
JP2006241144A5 true JP2006241144A5 (en) 2009-03-05
JP5011739B2 JP5011739B2 (en) 2012-08-29

Family

ID=37047899

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006024024A Active JP5011739B2 (en) 2005-02-03 2006-02-01 Pharmaceutical composition containing tetrahydro-2H-thiopyran-4-carboxamide derivative

Country Status (1)

Country Link
JP (1) JP5011739B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050326B2 (en) 2008-04-02 2015-06-09 Astellas Pharma Inc. Amido derivatives-contained pharmaceutical composition
EP2351565A1 (en) * 2008-10-20 2011-08-03 Astellas Pharma Inc. Medicine for preventing or treating pain related to herpes zoster
EP2513343A4 (en) * 2009-12-18 2013-11-13 Exodos Life Sciences Ltd Partnership Methods and compositions for treating inflammation of skin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4327249B2 (en) * 1995-12-29 2009-09-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Phenylthiazole derivatives with anti-herpesvirus properties
WO2000029399A1 (en) * 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
ES2247177T3 (en) * 2000-11-10 2006-03-01 Astellas Pharma Inc. DERIVATIVES OF AMIDA.
WO2003095435A1 (en) * 2002-05-09 2003-11-20 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives
JP2004026819A (en) * 2002-05-09 2004-01-29 Yamanouchi Pharmaceut Co Ltd Medicinal composition
JP3623228B1 (en) * 2003-08-08 2005-02-23 山之内製薬株式会社 Tetrahydro-2H-thiopyran-4-carboxamide derivative
TW200505894A (en) * 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative

Similar Documents

Publication Publication Date Title
JP2007533752A5 (en)
RU2412935C2 (en) Phenoxyacetic acids as activators of delta receptors ppar
HRP20160450T1 (en) Novel s-nitrosoglutathione reductase inhibitors
JP2008511586A5 (en)
JP2009528296A5 (en)
JP2007231005A5 (en)
RU2011110435A (en) MEDICINES OF METHYL HYDROFUMARATE, PHARMACEUTICAL COMPOSITIONS WITH THEM AND METHODS OF APPLICATION
JP2008516968A5 (en)
JP2006513238A5 (en)
JP2006526031A5 (en)
JP2004532209A5 (en)
AR048306A1 (en) DERIVATIVES OF AROMATIC CARBOXYLIC ACIDS WITH MODULATING CAPACITY OF INSULIN LEVELS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF METABOLIC DISORDERS RESPONDING TO THE REGULATION OF GPR40
CA2556944A1 (en) Thiazole derivative
RU2009118281A (en) HETEROCYCLIC MEK INHIBITORS AND WAYS OF THEIR APPLICATION
RU2420522C2 (en) New histone deacetylase inhibitor class
JP2008520594A5 (en)
JP2012255002A5 (en)
JP2005538089A5 (en)
RU2008129641A (en) CCR9 ACTIVITY INHIBITORS
JP2010511631A5 (en)
JP2009501704A5 (en)
JP2004507501A5 (en)
JP2005517643A5 (en)
JP2008510701A5 (en)
JP2007515467A5 (en)